Century Therapeutics develops allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for cancer and immune-mediated disease. The platform aims to create off-the-shelf immune cells that can be manufactured at scale rather than patient-specific autologous products. Its programs target oncology and related indications where standardized cell therapies could broaden access beyond current CAR-T models.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 109.2 | — | 76.6 | — |
| Q2 2025 | 0 | — | -32.5 | — |
| Q3 2025 | 0 | — | -34.4 | — |
| Q4 2025 | 0 | — | -19.2 | — |
| Q1 2026 | 0 | -100% | -21.6 | -128.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Fortress Value Acquisition Corp. V (FVAV), American Battery Technology Company (ABAT), CURRENC Group Inc. (CURR), GSR V Acquisition Corp. (GSRV), Freedom Metals Acquisition Corp. (FDMM), Artesian Resources Corporation (ARTNA)